Newron Pharmaceuticals SpA (FRA:NP5) Tariff Resilience Score: 0/10 (As of Jul. 06, 2026)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
61 GF Score
Price €13.90
GF Value €14.78
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Tariff Resilience Score?

Newron Pharmaceuticals SpA has the Tariff Resilience Score of 0, which implies that the company might have .

Newron Pharmaceuticals SpA has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Newron Pharmaceuticals SpA might have .

Newron Pharmaceuticals SpA  (FRA:NP5) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Newron Pharmaceuticals SpA Tariff Resilience Score Related Terms

FRA:NP5
61GF Score
Newron Pharmaceuticals SpA FRA:NP5
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.90 is trading 6% below its estimated GF Value™ of €14.78. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • Tariff Resilience Score: 0
  • GF Value™: €14.78 vs. price of €13.90 (6% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
61GF Score

Get the complete analysis for FRA:NP5

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.90
Price
€14.78
GF Value